

American journal of respiratory medicine  
DUP - General Collection  
W1 AM521NJ  
v. 2, no. 1  
2003

# American Journal of Respiratory Medicine™

DRUGS, DEVICES AND OTHER INTERVENTIONS

2003, Vol. 2, No. 1 (pp. 1-107)  
ISSN 1533-6633

Adis Drug Evaluation  
Cefepime

Allergic Rhinitis  
Comparing Intranasal Corticosteroids and Antihistamines

Asthma  
Clinical Usefulness of Inflammatory Markers  
Implications of Psychiatric Factors in Asthma  
Chlamydia pneumoniae Infections and Asthma

Infectious Diseases  
Optimizing Treatment Outcomes in Severe Community-Acquired Pneumonia

Obstructive Airways Disease  
COPD Outcomes in Patients taking Inhaled Corticosteroids/Long-Acting  $\beta$ -Agonists

Sleep Apnea  
Serotonin Agonists and Antagonists in Obstructive Sleep Apnea

Available Online



PROPERTY OF THE  
NATIONAL  
LIBRARY OF  
MEDICINE

**adis**  
INTERNATIONAL  
A Wolters Kluwer Company

AUCKLAND • BARCELONA • BUENOS AIRES • CHESTER • HONG KONG • MADRID

**DOCKET**  
**ALARM**

**Contents**

<b>Current Opinion</b>	Psychiatric Factors in Asthma: Implications for Diagnosis and Therapy <i>S Rietveld, TL Creer</i>	1-10
<b>Leading Articles</b>	Clinical Usefulness of Inflammatory Markers in Asthma <i>PAB Wark, PG Gibson</i>	11-19
	Serotonin Agonists and Antagonists in Obstructive Sleep Apnea: Therapeutic Potential <i>SC Veasey</i>	21-29
	<i>Chlamydia pneumoniae</i> Infections in Asthma: Clinical Implications <i>M Gencay, M Roth</i>	31-38
<b>Therapy in Practice</b>	Optimizing Treatment Outcomes in Severe Community-Acquired Pneumonia <i>F Rodríguez de Castro, A Torres</i>	39-54
<b>Review Article</b>	Comparison of Intranasal Corticosteroids and Antihistamines in Allergic Rhinitis: A Review of Randomized, Controlled Trials <i>LP Nielsen, R Dahl</i>	55-65
<b>Original Research Article</b>	Inhaled Corticosteroids With/Without Long-Acting $\beta$ -Agonists Reduce the Risk of Rehospitalization and Death in COPD Patients <i>JB Soriano, VA Kiri, NB Pride, J Vestbo</i>	67-74
<b>Adis Drug Evaluation</b>	Cefepime: A Review of its Use in the Management of Hospitalized Patients with Pneumonia <i>TM Chapman, CM Perry</i>	75-107

American Journal of Respiratory Medicine is indexed in *Chemical Abstracts*. Indexing by all major biomedical databases has been applied for. Individual articles are available through the ADONIS document delivery system and are available on-line via the World Wide Web through Ingenta. Further details are available from the publisher.

This material was copied  
at the NLM and may be  
Subject US Copyright Laws



**International Editorial Board**

N.C. Barnes, *London, England*  
 E.D. Bateman, *Cape Town, South Africa*  
 A. Bufe, *Bochum, Germany*  
 W.W. Busse, *Madison, WI, USA*  
 J. Brostoff, *London, England*  
 K.F. Chung, *London, England*  
 H.G. Colt, *Orange, CA, USA*  
 D.B. Coultas, *Jacksonville, FL, USA*  
 B.A. Cunha, *Mineola, NY, USA*  
 L.M. DuBuske, *Boston, MA, USA*  
 J.A. Elias, *New Haven, CT, USA*  
 R. Feld, *Toronto, ON, Canada*  
 J.M. Fitzgerald, *Vancouver, BC, Canada*  
 P.G. Gibson, *Newcastle, NSW, Australia*  
 H.L. Halliday, *Belfast, Northern Ireland*  
 S.T. Holgate, *Southampton, England*  
 S.S. Hurd, *Gaithersburg, MD, USA*  
 N.N. Jarjour, *Madison, WI, USA*  
 E.F. Juniper, *Bosham, England*  
 N. Keicho, *Tokyo, Japan*  
 S.C. Lazarus, *San Francisco, CA, USA*  
 G.A. Lillington, *Palo Alto, CA, USA*  
 R.J. Martin, *Denver, CO, USA*  
 E.R. McFadden, *Cleveland, OH, USA*  
 P.G. Noone, *Chapel Hill, NC, USA*  
 S.I. Rennard, *Omaha, NE, USA*  
 R.E. Ruffin, *Adelaide, SA, Australia*  
 C.A. Sorkness, *Madison, WI, USA*  
 D.P. Speert, *Vancouver, BC, Canada*  
 S. Suissa, *Montreal, QC, Canada*  
 W.C. Tan, *Singapore*  
 D.R. Taylor, *Dunedin, New Zealand*  
 M.M. Weinberger, *Iowa City, IA, USA*

**Aim and Scope:** The *American Journal of Respiratory Medicine* publishes a regular program of independent review articles covering all aspects of the management of respiratory disorders, particularly the place in therapy of newer and established drugs and devices, with the aim of promoting rational therapy and effective patient management within the discipline of respiratory medicine.

The Journal includes:

- Leading/current opinion articles providing an overview of contentious or emerging areas and key regulatory and ethical issues
- Definitive reviews on a broad range of topics relating to the management of respiratory disorders
- Therapy in practice reviews covering optimum management of specific conditions
- Adis Drug Evaluations reviewing the properties and place in therapy of both newer and established drugs
- Adis Drug Profiles reviewing innovations in patient management with expert commentaries
- Original research articles.

All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.

**Editor:** Rosie Stather

**Publication Manager:** Hera Millard

**Editorial Office and Inquiries:** Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand. Information on the preparation of manuscripts will be provided to authors.

E-mail: [respiratory@adis.com](mailto:respiratory@adis.com)

<http://www.adis.com/res>

**American Journal of Respiratory Medicine** (ISSN 1175-6365): 6 issues are published annually by Adis International Limited. Annual 2003 subscription price: institutional \$US599; personal \$US195. Subscription orders must be prepaid. All subscriptions to Adis titles include electronic access at no extra cost (further subscription information is given at the back of each issue).

**Policy Statement:** Although great care has been taken in compiling the content of this publication, the publisher and its servants are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not necessarily reflect the views of the Publisher, Editor or Editorial Board.

**Copyright:** © 2003 Adis International Ltd. All rights reserved throughout the world and in all languages. No part of this publication may be reproduced, transmitted or stored in any form or by any means either mechanical or electronic, including photocopying, recording, or through an information storage and retrieval system, without the written permission of the copyright holder. The appearance of the code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for the personal or internal use of specific clients. This consent is given provided that the fee of \$US30 per copy is paid directly to the Copyright Clearance Center Inc., 222 Rosewood Drive, Danvers, Massachusetts 01923, USA, for copying beyond that permitted by sections 107 or 108 of the US Copyright Law. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

This material was copied  
at the NLM and may be  
Subject US Copyright Laws



# Comparison of Intranasal Corticosteroids and Antihistamines in Allergic Rhinitis

## A Review of Randomized, Controlled Trials

Lars P. Nielsen<sup>1,2</sup> and Ronald Dahl<sup>2</sup>

1 Department of Clinical Pharmacology, University of Aarhus, Aarhus, Denmark

2 Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark

### Contents

Abstract	55
1. Antihistamines	56
1.1 General Considerations	56
1.2 Oral Antihistamines	56
1.3 Intranasal Antihistamines	56
2. Corticosteroids	57
2.1 General Considerations	57
2.2 Intranasal Corticosteroids	57
3. Comparing Antihistamines and Intranasal Corticosteroids in Allergic Rhinitis	58
3.1 Perennial Allergic Rhinitis	58
3.2 Seasonal Allergic Rhinitis	58
3.3 Combination of Antihistamines and Intranasal Corticosteroids	60
3.4 Safety	60
3.5 Cost-Effectiveness	61
4. Conclusion	61

### Abstract

For several years there has been discussion of whether first-line pharmacological treatment of allergic rhinitis should be antihistamines or intranasal corticosteroids. No well documented, clinically relevant differences seem to exist for individual nonsedating antihistamines in the treatment of allergic rhinitis. Likewise, the current body of literature does not seem to favor any specific intranasal corticosteroid. When comparing efficacy of antihistamines and intranasal corticosteroids in allergic rhinitis, present data favor intranasal corticosteroids. Interestingly, data do not support antihistamines as superior in treating conjunctivitis associated with allergic rhinitis. Safety data from comparative studies in allergic rhinitis do not indicate differences between antihistamines and intranasal corticosteroids. Combining antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis does not provide additional beneficial effects to intranasal corticosteroids alone.

Considering present data, intranasal corticosteroids seem to offer superior relief in allergic rhinitis, when compared with antihistamines.

Allergic rhinitis is a disease characterized by nasal obstruction, rhinorrhea, sneezing and nasal itch and often accompanied by conjunctivitis. It is elicited by IgE-mediated allergic inflammation of the nasal mucosa. The disease prevalence is 10–20%

of the population in industrialized countries<sup>[1]</sup> and seems to be increasing.<sup>[2,3]</sup> Although allergic rhinitis is not a life-threatening disease, it can severely affect patients' quality of life<sup>[4-6]</sup> and can cause comorbidity from other diseases, such as asthma, sinusitis,

This material was copied  
at the NLM and may be  
Subject US Copyright Laws

otitis media and conjunctivitis.<sup>171</sup> Allergic rhinitis can be either seasonal, i.e. present at certain times of the year such as during the pollen season, or perennial, i.e. present at all times of the year.

Applicable therapeutic initiatives in allergic rhinitis are allergen avoidance, allergen immunotherapy and pharmacological intervention. This review considers first-line pharmacological treatment of allergic rhinitis, in which two main treatment options have evolved, i.e. antihistamines and intranasal corticosteroids. The choice between these options has been extensively discussed since the introduction of intranasal corticosteroid treatment.<sup>181</sup> Evidence presented in this review considers only data obtained in patients with allergic rhinitis. Medical literature including abstracts and randomized trials published in the English language during the period 1966–2001 on antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis were identified using Medline.

## 1. Antihistamines

### 1.1 General Considerations

Histamine is the major pathophysiological mediator of allergic rhinitis, almost exclusively exerting its action through stimulation of the H<sub>1</sub> receptor. Whether other histamine receptors have any effect in allergic rhinitis remains to be clarified. Antihistamines in the treatment of allergic rhinitis are, thus, H<sub>1</sub> receptor antagonists.<sup>19,101</sup> An additional anti-inflammatory effect of H<sub>1</sub> antihistamines has been proposed, as some newer compounds seem to influence cytokine production, mediator release or inflammatory cell flux.<sup>111-191</sup> However, other studies have been unable to reproduce such findings.<sup>120-231</sup> Whether antihistamines offer additional and clinically relevant anti-inflammatory effects along with their inhibition of histamine action needs further clarification.

### 1.2 Oral Antihistamines

Numerous H<sub>1</sub> receptor antagonists have been developed over the years. For oral use, these can roughly be divided into older, first-generation (e.g. chlorpheniramine, diphenhydramine, promethazine and triprolidine) and newer, second-generation antihistamines (acrivastine, astemizole, cetirizine, ebastine, fexofenadine, loratadine, mizolastine and terfenadine). This review deals with the newer antihistamines, as use of the older drugs in allergic rhinitis is limited by their adverse effects, mainly sedation and anticholinergic activity.

All of the newer antihistamines are effective in the treatment of allergic rhinitis by decreasing nasal itching, sneezing and rhinorrhea, but have a poor effect upon nasal congestion.<sup>124-311</sup> They

are also effective upon conjunctivitis and recent results seem to indicate some influence on lower airway symptoms which often co-exists with allergic rhinitis.<sup>132,331</sup>

Moreover, the pharmacokinetic profile of these drugs is advantageous when compared with that of the older ones.<sup>1341</sup> They have an onset of action within 1–2 hours, lasting for 12–24 hours, except for acrivastine, which has to be given at 8-hour intervals. With the exception of cetirizine and fexofenadine, which are excreted almost unchanged, the drugs in this group are metabolized via the hepatic cytochrome P450 (CYP) system by CYP3A. As a number of other compounds (antimycotic conazoles, macrolide antibacterials and grapefruit juice) are substrates for this enzyme, this obviously provides a theoretical risk for interactions.<sup>1351</sup> This is probably a contributing factor to the occurrence of severe cardiac arrhythmias (such as ‘torsade de pointes’) and deaths, which have been described following treatment with terfenadine and astemizole.<sup>136-381</sup> These effects seem to be enabled through a quinidine-like action, causing a prolongation of the QT interval.<sup>139,401</sup> At present, no clinical evidence has demonstrated cardiac adverse effects from other second-generation antihistamines, when considered at therapeutically appropriate levels. However, in a consensus statement on the treatment of allergic rhinitis the European Academy of Allergology and Clinical Immunology recommends that antihistamines that are metabolized by CYP450 or have quinidine-like actions be avoided in risk groups, i.e. patients with impaired hepatic function or cardiac arrhythmia.<sup>1411</sup>

Astemizole can also act as an appetite stimulant and result in increased bodyweight.<sup>142,431</sup> The cause of this action remains obscure, although a CNS-mediated mechanism, such as serotonin antagonism, could be speculated. However, whether this adverse effect is seen exclusively with astemizole remains unclear, as data regarding this parameter are lacking for other second-generation antihistamines.

While CNS-related adverse effects were a major characteristic of the first-generation antihistamines, the piperazine/piperidine-derived structures of the newer generation reduce their CNS penetration, although sedative effects have been described for some of the compounds, e.g. acrivastine<sup>1441</sup> and cetirizine.<sup>1451</sup> The binding affinity to muscarinic receptors is also decreased. With the exception of cardiac adverse effects, this leaves second-generation antihistamines with a therapeutic index superior to that of first-generation antihistamines.

### 1.3 Intranasal Antihistamines

Azelastine and levocabastine are two newer H<sub>1</sub> receptor antagonists for topical use. When applied intranasally, both have

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.